Literature DB >> 7828137

Correlation of ganglioside patterns of primary brain tumors with survival.

C C Sung1, D K Pearl, S W Coons, B W Scheithauer, P C Johnson, M Zheng, A J Yates.   

Abstract

BACKGROUND: Classification/grading schemes for brain tumors are based mainly on histologic examinations, but these have major limitations, which has led to a search for more objective prognostic markers. Gangliosides have several biologic effects relevant to tumors, and ganglioside compositions of primary brain tumors correlate with diagnosis. This led to the authors' hypothesis that ganglioside patterns of brain tumors might be useful as prognostic indicators.
METHODS: Gangliosides in primary brain tumors of different histologic types from 84 patients were analyzed. Specific ganglioside patterns and several other relevant variables were examined for associations with survival using a Cox proportional hazards model. Kaplan-Meier survival curves were analyzed using the log-rank test.
RESULTS: Patients in whom less than 30% of total tumor gangliosides consisted of 1b pathway gangliosides (GD1b, GT1b, and GQ1b) had significantly higher risk ratios than those with more than 30% 1b gangliosides (P approximately 0.03). The presence of 6'-LM1 (NeuAc alpha 2-->6Gal beta 1-->4Glc-NAc beta 1-->3Gal beta 1-->4Glc beta 1-->1Cer was also associated with a higher risk ratio (P approximately 0.007). Combinations of 1b gangliosides and 6'-LM1 identified three groups of patients regardless of histologic diagnosis. Group A, with less than 30% 1b and the presence of 6'-LM1, had a median survival time of 331 days. Group B, with less than 30% 1b but no 6'-LM1, had a median survival time of more than 698 days. Group C, with more than 30% 1b had a median survival time of more than 776 days.
CONCLUSIONS: The correlation of ganglioside patterns with survival in this initial investigation suggests the potential of 1b gangliosides and 6'-LM1 to be used as prognostic indicators. Continuing research is being conducted to assess this possibility prospectively.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7828137     DOI: 10.1002/1097-0142(19950201)75:3<851::aid-cncr2820750317>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Induction of GM1a/GD1b synthase triggers complex ganglioside expression and alters neuroblastoma cell behavior; a new tumor cell model of ganglioside function.

Authors:  Lixian Dong; Yihui Liu; Anamaris M Colberg-Poley; Karen Kaucic; Stephan Ladisch
Journal:  Glycoconj J       Date:  2011-04-26       Impact factor: 2.916

2.  Molecular mechanisms of GD3-induced apoptosis in U-1242 MG glioma cells.

Authors:  O M Omran; H E Saqr; Allan J Yates
Journal:  Neurochem Res       Date:  2006-10-17       Impact factor: 3.996

3.  Low complex ganglioside expression characterizes human neuroblastoma cell lines.

Authors:  Simone Hettmer; Stephan Ladisch; Karen Kaucic
Journal:  Cancer Lett       Date:  2005-01-07       Impact factor: 8.679

4.  Glycolipids and myelin proteins in human oligodendrogliomas.

Authors:  C C Sung; R Collins; J Li; D K Pearl; S W Coons; B W Scheithauer; P C Johnson; A J Yates
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

5.  Glioma growth inhibition by neurostatin and O-But GD1b.

Authors:  Beatriz Valle-Argos; Diego Gómez-Nicola; Manuel Nieto-Sampedro
Journal:  Neuro Oncol       Date:  2010-07-08       Impact factor: 12.300

6.  Gangliosides and neutral glycolipids in ependymal, neuronal and primitive neuroectodermal tumors.

Authors:  A J Yates; T K Franklin; P McKinney; R Collins; T Comas; C P Boesel; D K Pearl
Journal:  J Mol Neurosci       Date:  1999-04       Impact factor: 3.444

7.  Ganglioside composition and histology of a spontaneous metastatic brain tumour in the VM mouse.

Authors:  M El-Abbadi; T N Seyfried; A J Yates; C Orosz; M C Lee
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

8.  Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid.

Authors:  S Hettmer; R McCarter; S Ladisch; K Kaucic
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

9.  An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.

Authors:  Shoko Yoshida; Haruhiko Kawaguchi; Shigeki Sato; Ryuzo Ueda; Koichi Furukawa
Journal:  Jpn J Cancer Res       Date:  2002-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.